Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label switch study of PRX-102 in Fabry disease patients previously treated with Replagal
NL-OMON47873Phase 3Active, not recruiting
- Sponsor
- Protalix BioTherapeutics
- Start
- Aug 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Protalix BioTherapeutics. Primary endpoints: Change from baseline in clinical laboratory tests, Change from baseline in physical examination and 6 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON47873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47873.